Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at 63.6 billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than 200 research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Sales from the United States contributed more than 38 billion U.S. dollars towards Pfizer's total revenue of around 63.6 billion U.S. dollars in 2023. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to company revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.

Revenues generated from outside the United States accounted for almost two thirds of Pfizer's total revenue in 2024. During that year, the company generated revenues of roughly 25 billion U.S. dollars in countries outside the United States. China emerges as an important market Pfizer sells its pharmaceutical products in more than 120 countries worldwide, with the United States, China, and Japan being among the major national markets. In 2024, the United States alone contributed a share of more than 60 percent. In terms of geographic area, emerging markets – which include China – generated revenues of approximately 8.9 billion U.S. dollars in 2024. Analyzing Pfizer’s global operations In 2024, Pfizer had approximately 81,000 employees worldwide. The American company had 37 manufacturing sites in countries ranging from Belgium to Singapore, each producing products that serviced the company’s commercial division. Pfizer also had several facilities that focused on research and development projects, many of which were located in North America.

In fiscal year 2024, Pfizer's revenue by geographical region are as follows: Developed Rest Of World: $16.06B, Emerging Markets: $8.88B, UNITED STATES: $38.69B.

In 2024, Pfizer generated total revenues of some 63.6 billion U.S. dollars. For Q4, 2024, the company reported revenues of some 17.8 billion U.S. dollars. That was significantly higher than 14.6 billion dollars in Q4 2023. By failing to prepare, you are preparing to fail The majority of Pfizer’s revenue comes from the manufacture and sale of its products. Pharmaceutical companies are always planning for the future, looking for ways to offset the impact felt when those products start to lose market exclusivity. The development of products is essential for the continued growth of the company, and investing in research and development (R&D) is one way of identifying new, innovative medicines. Pfizer’s R&D expenditure stood at around 10.8 billion U.S. dollars in 2024. Why Pfizer’s revenues decreased until 2020? Pfizer averaged quarterly revenues of around 13.2 billion U.S. dollars in the four years from the start of 2016 to the end of 2019 – this is considerably lower than the 16.7 billion U.S. dollars the company averaged per quarter in 2010. One reason for the decline was competition from generic drugs that entered the market when key patents expired. Pfizer lost the market exclusivity for its Lipitor product at the end of 2011, and revenues were greatly affected as a consequence. Additionally, following a review of its product portfolio, Pfizer’s revenues were also impacted by the decision to spin off some of its business segments, such as its animal health division in 2013 and its Upjohn business in 2020.

Pfizer reported $410M in Net Income for its fiscal quarter ending in December of 2024. Data for Pfizer | PFE - Net Income including historical, tables and charts were last updated by Trading Economics this last March in 2025.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data was reported at 1,753,000.000 USD th in Jun 2018. This records an increase from the previous number of 812,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,980,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 3,433,000.000 USD th in Dec 2017 and a record low of 707,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

This statistic depicts revenues of pharmaceutical company Pfizer from 2022 to 2024, by segment. The Primary Care segment, which includes the COVID-19 vaccine Comirnaty, is the company's strongest segment. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. Due to the Upjohn spin-off during 2020 and the Consumer Healthcare business merger with GSK's consumer health segment to form a new joint venture in 2019, only the Biopharma segment remained.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data was reported at 2,835,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,314,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data is updated quarterly, averaging 3,304,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 5,806,000.000 USD th in Dec 2014 and a record low of 1,174,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data was reported at 2,340,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,591,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data is updated quarterly, averaging 2,277,000.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 4,442,000.000 USD th in Dec 2015 and a record low of 778,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

This dataset is about companies and is filtered where the company includes Pfizer, featuring 5 columns: city, company, country, foundation year, and revenues. The preview is ordered by revenues (descending).

The graph depicts Pfizer's top 10 products based on revenue in 2024. Pfizer Inc. is a multinational pharmaceutical corporation. The company is headquartered in Midtown Manhattan, New York City. In 2024, Pfizer's top product was Eliquis. COVID-19 vaccine Comirnaty, on the other hand, showed another dramatic decline in sales from 11.2 billion U.S. dollars in 2023 to 5.4 billion dollars. Pfizer's top productsPfizer is a pharmaceutical corporation headquartered in New York City, United States. It was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York, where they produced an antiparasitic called santonin. Today, Pfizer produces pharmaceutical products for a wide range of medical sectors that include but are not limited to immunology, cardiology, and neurology. In 2024, Pfizer generated a total revenue of 63.6 billion U.S. dollars worldwide, with oncology products accumulating some 15.6 billion U.S. dollars.Some of Pfizer’s well-known products - although with expired patent protection - include Lyrica and Lipitor, which generated around 3.3 and five billion U.S. dollars in revenue, respectively, in 2019. Pregabalin, marketed as Lyrica, is an anticonvulsant drug used to treat disorders such as epilepsy, diabetic peripheral neuropathy, and fibromyalgia. Lipitor, one of Pfizer’s more well-known products, generated revenues of 12.9 billion U.S. dollars in 2006, however, after Pfizer’s patent on Lipitor expired in 2011, revenue has fallen to under two billion U.S. dollars. Currently, generic forms of atorvastatin (Lipitor) are available. Lipitor is a statin that is used to lower blood cholesterol and to prevent cardiovascular diseases.

Pfizer reported $171M in Interest Income for its fiscal quarter ending in December of 2024. Data for Pfizer | PFE - Interest Income including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Pfizer's annual net income per employee was $99.15K in fiscal year 2024. The net income per employeeincreased$75.07Kfrom $24.08K(in 2023) to $99.15K (in 2024), representing a 311.75% year-over-year growth.

United States US: PFE: Revenue (External): Innovative Health Product: US data was reported at 9,121,000.000 USD th in Jun 2018. This records an increase from the previous number of 4,544,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: US data is updated quarterly, averaging 9,025,500.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 18,460,000.000 USD th in Dec 2017 and a record low of 2,972,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Pfizer forecasts 2025 sales between $61B-$64B, meeting Wall Street expectations, amid strategic moves like cost cuts and leadership in R&D.

Pfizer surpasses Q4 and FY 2024 earnings expectations, with a strategic focus on cost reductions and revenue growth, overcoming challenges such as patent expirations and Medicare negotiations.

United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data was reported at 2,394,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,158,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data is updated quarterly, averaging 2,571,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 4,381,000.000 USD th in Dec 2017 and a record low of 872,000.000 USD th in Mar 2016. United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: International data was reported at 10,238,000.000 USD th in Sep 2018. This records an increase from the previous number of 6,891,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International data is updated quarterly, averaging 8,591,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 14,836,000.000 USD th in Dec 2015 and a record low of 3,220,000.000 USD th in Mar 2017. United States US: PFE: Revenue (External): Essential Health Product: International data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: US data was reported at 4,859,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,379,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: US data is updated quarterly, averaging 4,849,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 9,596,000.000 USD th in Dec 2016 and a record low of 1,731,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.